Immutep’s LAG-3 drug scores in Phase 2b head and neck cancer test
Immutep’s protein-based cancer treatment has succeeded in a mid-stage study in patients with head and neck squamous cell carcinoma, spurring discussions with regulators on a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
